ProMIS Neurosciences PMN
NASDAQ PMN
$14.51 -0.40 (-2.68%)
As of: Aug 21, 2026 · 3:59 PM EDT

ProMIS Neurosciences (PMN) Net Equity Issued and Repurchased (2021 - 2025)

ProMIS Neurosciences' (PMN) quarterly Net Equity Issued and Repurchased came in at $708468.0 in Q3 2025, up 272.34% on a QoQ basis from $190274.0 in Q1 2024.

ProMIS Neurosciences (PMN) Net Equity Issued and Repurchased (2021 - 2025) Analysis & Trends

ProMIS Neurosciences (PMN) has 3 years of Net Equity Issued and Repurchased data on file, last reported at $708468.0 in Q3 2025.

  • Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $708468.0 in Q3 2025, while the trailing twelve-month figure through Dec 2025 was $708468.0 (up 272.34% YoY) and the FY2025 annual result came in at $708468.0, up 272.34% from the prior year.
  • Net Equity Issued and Repurchased grew to $708468.0 in Q3 2025, from $190274.0 in the prior quarter.
  • In the past five years, Net Equity Issued and Repurchased ranged from a high of $708468.0 in Q3 2025 to a low of $445.0 in Q4 2021.
  • A 3-year average of $299729.0 and a median of $190274.0 in 2024 frame the typical range for Net Equity Issued and Repurchased.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 49.20 Mn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn -
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn -
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn -
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn -
9 Royalty Pharma 27.27 Bn 26.43 Bn - -
10 ProMIS Neurosciences 132.34 Mn 78.87 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2025 708,468.00
Sep 30, 2025 708,468.00
Mar 31, 2024 190,274.00
Mar 31, 2024 190,274.00
Dec 31, 2021 445.00
Dec 31, 2021 445.00